MURRIETA, CA--(Marketwire - July 28, 2008) - CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today filed a Schedule 14C Information Statement with the Securities and Exchange Commission reporting majority shareholder approval on proposals that effect the capital structure of the company. The changes were initiated by the company’s Board of Directors in order to properly position CLX to execute an acquisition strategy over the next several months.
